Avibactam sodium/Ceftazidime hydrate

Pre-clinicalRecruiting

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Infectious Diseases

Conditions

Infectious Diseases

Trial Timeline

Mar 15, 2026 → Mar 30, 2029

NCT ID

NCT06864585

About Avibactam sodium/Ceftazidime hydrate

Avibactam sodium/Ceftazidime hydrate is a pre-clinical stage product being developed by Pfizer for Infectious Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06864585. Target conditions include Infectious Diseases.

What happened to similar drugs?

4 of 19 similar drugs in Infectious Diseases were approved

Approved (4) Terminated (4) Active (11)

✅AdalimumabAbbVieApproved

✅Daptomycin + Standard of Care (SOC)MerckApproved

✅TigecyclinePfizerApproved

✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved

🔄LevofloxacinJohnson & JohnsonPhase 3

🔄Tedizolid Phophate + Antibiotic comparator + Aztreonam + MetronidazoleMerckPhase 3

❌Daptomycin + Vancomycin + TeicoplaninNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06864585	Pre-clinical	Recruiting	Mar 15, 2026	Mar 30, 2029	Infectious Diseases

Competing Products

20 competing products in Infectious Diseases

See all competitors

Product	Company	Stage	Hype Score
levofloxacin	Johnson & Johnson	Phase 2/3	38
Levofloxacin	Johnson & Johnson	Phase 3	40
Adalimumab	AbbVie	Approved	43
Acalabrutinib + Rabeprazole	AstraZeneca	Phase 1	29
Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam	Merck	Phase 2	35
Daptomycin + Standard of Care (SOC)	Merck	Approved	43
MK-7655 + Imipenem + Cilastatin + Caffeine + Midazolam + Omeprazole	Merck	Phase 1	29
TR-701 200 mg + TR-701 300 mg + TR-701 400 mg	Merck	Phase 2	35
Tedizolid Phophate + Antibiotic comparator + Aztreonam + Metronidazole	Merck	Phase 3	40
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
Daptomycin + Vancomycin + Teicoplanin	Novartis	Phase 3	32
PTK 0796 + linezolid + moxifloxacin	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
valacyclovir	Roche	Phase 1/2	32
Filgotinib + Placebo to match filgotinib + Prednisone	Gilead Sciences	Phase 2	27
Tigecycline + vancomycin with aztreonam	Pfizer	Phase 3	40
Tigecycline	Pfizer	Approved	43